Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.34
PKI's Cash-to-Debt is ranked lower than
81% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.94 vs. PKI: 0.34 )
Ranked among companies with meaningful Cash-to-Debt only.
PKI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15  Med: 0.33 Max: 2.06
Current: 0.34
0.15
2.06
Equity-to-Asset 0.50
PKI's Equity-to-Asset is ranked lower than
61% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. PKI: 0.50 )
Ranked among companies with meaningful Equity-to-Asset only.
PKI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.5 Max: 0.63
Current: 0.5
0.32
0.63
Interest Coverage 6.82
PKI's Interest Coverage is ranked lower than
77% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 55.24 vs. PKI: 6.82 )
Ranked among companies with meaningful Interest Coverage only.
PKI' s Interest Coverage Range Over the Past 10 Years
Min: 2.25  Med: 6.71 Max: 10.97
Current: 6.82
2.25
10.97
Piotroski F-Score: 8
Altman Z-Score: 3.37
Beneish M-Score: -2.63
WACC vs ROIC
9.36%
8.60%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 13.38
PKI's Operating Margin % is ranked higher than
76% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.35 vs. PKI: 13.38 )
Ranked among companies with meaningful Operating Margin % only.
PKI' s Operating Margin % Range Over the Past 10 Years
Min: 4.75  Med: 9.33 Max: 13.38
Current: 13.38
4.75
13.38
Net Margin % 11.08
PKI's Net Margin % is ranked higher than
84% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. PKI: 11.08 )
Ranked among companies with meaningful Net Margin % only.
PKI' s Net Margin % Range Over the Past 10 Years
Min: 0.4  Med: 7.5 Max: 22.94
Current: 11.08
0.4
22.94
ROE % 11.12
PKI's ROE % is ranked higher than
70% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.09 vs. PKI: 11.12 )
Ranked among companies with meaningful ROE % only.
PKI' s ROE % Range Over the Past 10 Years
Min: 0.41  Med: 8.2 Max: 22
Current: 11.12
0.41
22
ROA % 5.54
PKI's ROA % is ranked higher than
71% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.86 vs. PKI: 5.54 )
Ranked among companies with meaningful ROA % only.
PKI' s ROA % Range Over the Past 10 Years
Min: 0.22  Med: 4.28 Max: 12.48
Current: 5.54
0.22
12.48
ROC (Joel Greenblatt) % 67.72
PKI's ROC (Joel Greenblatt) % is ranked higher than
85% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. PKI: 67.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PKI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 26.99  Med: 51.1 Max: 76.53
Current: 67.72
26.99
76.53
3-Year Revenue Growth Rate 0.30
PKI's 3-Year Revenue Growth Rate is ranked lower than
61% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. PKI: 0.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PKI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.7  Med: 1.1 Max: 17.9
Current: 0.3
-10.7
17.9
3-Year EBITDA Growth Rate 4.60
PKI's 3-Year EBITDA Growth Rate is ranked higher than
56% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. PKI: 4.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PKI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -21  Med: 4.6 Max: 35.4
Current: 4.6
-21
35.4
3-Year EPS without NRI Growth Rate 8.40
PKI's 3-Year EPS without NRI Growth Rate is ranked higher than
62% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. PKI: 8.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PKI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -79  Med: 9.3 Max: 384.9
Current: 8.4
-79
384.9
GuruFocus has detected 4 Warning Signs with PerkinElmer Inc $PKI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PKI's 10-Y Financials

Financials (Next Earnings Date: 2017-05-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PKI Guru Trades in Q1 2016

Paul Tudor Jones 18,020 sh (New)
PRIMECAP Management 3,497,630 sh (+5.92%)
Jim Simons Sold Out
Steven Cohen Sold Out
Chuck Royce Sold Out
Ken Fisher 655,760 sh (-0.89%)
» More
Q2 2016

PKI Guru Trades in Q2 2016

Ray Dalio 9,100 sh (New)
Jim Simons 29,300 sh (New)
Ken Fisher 685,785 sh (+4.58%)
PRIMECAP Management 3,450,105 sh (-1.36%)
Paul Tudor Jones 13,578 sh (-24.65%)
» More
Q3 2016

PKI Guru Trades in Q3 2016

Ken Fisher 697,696 sh (+1.74%)
PRIMECAP Management 3,476,530 sh (+0.77%)
Ray Dalio Sold Out
Jim Simons Sold Out
Paul Tudor Jones 11,623 sh (-14.40%)
» More
Q4 2016

PKI Guru Trades in Q4 2016

Murray Stahl 5,700 sh (New)
PRIMECAP Management 3,506,130 sh (+0.85%)
Paul Tudor Jones Sold Out
Ken Fisher 666,941 sh (-4.41%)
» More
» Details

Insider Trades

Latest Guru Trades with PKI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 8071
Compare:NYSE:BIO, NAS:BASI » details
Traded in other countries:PKN.Germany,
PerkinElmer Inc is a provider of technology, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets.

PerkinElmer provides instruments, consumables, and services to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments: human health business, which includes diagnostics and research, and environmental health, composed of industrial, environmental, and food applications. PerkinElmer offers products and services ranging from genetic screening to environmental analytical tools.

Ratios

vs
industry
vs
history
PE Ratio 27.34
PKI's PE Ratio is ranked higher than
56% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.70 vs. PKI: 27.34 )
Ranked among companies with meaningful PE Ratio only.
PKI' s PE Ratio Range Over the Past 10 Years
Min: 5.3  Med: 27.16 Max: 3165
Current: 27.34
5.3
3165
Forward PE Ratio 20.66
PKI's Forward PE Ratio is ranked higher than
58% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PKI: 20.66 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 29.57
PKI's PE Ratio without NRI is ranked higher than
54% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.43 vs. PKI: 29.57 )
Ranked among companies with meaningful PE Ratio without NRI only.
PKI' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.52  Med: 27.82 Max: 2724
Current: 29.57
11.52
2724
Price-to-Owner-Earnings 23.54
PKI's Price-to-Owner-Earnings is ranked higher than
62% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.53 vs. PKI: 23.54 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PKI' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.67  Med: 21.57 Max: 1169.39
Current: 23.54
4.67
1169.39
PB Ratio 2.96
PKI's PB Ratio is ranked higher than
57% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.38 vs. PKI: 2.96 )
Ranked among companies with meaningful PB Ratio only.
PKI' s PB Ratio Range Over the Past 10 Years
Min: 0.88  Med: 1.91 Max: 2.97
Current: 2.96
0.88
2.97
PS Ratio 3.04
PKI's PS Ratio is ranked higher than
54% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.29 vs. PKI: 3.04 )
Ranked among companies with meaningful PS Ratio only.
PKI' s PS Ratio Range Over the Past 10 Years
Min: 0.72  Med: 1.81 Max: 3.04
Current: 3.04
0.72
3.04
Price-to-Free-Cash-Flow 20.03
PKI's Price-to-Free-Cash-Flow is ranked higher than
55% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.41 vs. PKI: 20.03 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PKI' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.79  Med: 21.74 Max: 93.23
Current: 20.03
7.79
93.23
Price-to-Operating-Cash-Flow 18.19
PKI's Price-to-Operating-Cash-Flow is ranked higher than
51% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.08 vs. PKI: 18.19 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PKI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.31  Med: 17.84 Max: 42.63
Current: 18.19
6.31
42.63
EV-to-EBIT 24.67
PKI's EV-to-EBIT is ranked lower than
60% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.11 vs. PKI: 24.67 )
Ranked among companies with meaningful EV-to-EBIT only.
PKI' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.6  Med: 24.35 Max: 59.2
Current: 24.67
10.6
59.2
EV-to-EBITDA 18.30
PKI's EV-to-EBITDA is ranked lower than
60% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 15.75 vs. PKI: 18.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
PKI' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7  Med: 16.15 Max: 25.5
Current: 18.3
7
25.5
PEG Ratio 2.13
PKI's PEG Ratio is ranked higher than
67% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.93 vs. PKI: 2.13 )
Ranked among companies with meaningful PEG Ratio only.
PKI' s PEG Ratio Range Over the Past 10 Years
Min: 0.58  Med: 2.65 Max: 181.36
Current: 2.13
0.58
181.36
Shiller PE Ratio 38.89
PKI's Shiller PE Ratio is ranked higher than
53% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.08 vs. PKI: 38.89 )
Ranked among companies with meaningful Shiller PE Ratio only.
PKI' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.4  Med: 28.59 Max: 39.85
Current: 38.89
14.4
39.85
Current Ratio 1.97
PKI's Current Ratio is ranked lower than
61% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. PKI: 1.97 )
Ranked among companies with meaningful Current Ratio only.
PKI' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 1.68 Max: 2.11
Current: 1.97
0.96
2.11
Quick Ratio 1.56
PKI's Quick Ratio is ranked lower than
63% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.08 vs. PKI: 1.56 )
Ranked among companies with meaningful Quick Ratio only.
PKI' s Quick Ratio Range Over the Past 10 Years
Min: 0.72  Med: 1.27 Max: 1.7
Current: 1.56
0.72
1.7
Days Inventory 94.49
PKI's Days Inventory is ranked lower than
58% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.07 vs. PKI: 94.49 )
Ranked among companies with meaningful Days Inventory only.
PKI' s Days Inventory Range Over the Past 10 Years
Min: 65.31  Med: 78.25 Max: 94.49
Current: 94.49
65.31
94.49
Days Sales Outstanding 73.43
PKI's Days Sales Outstanding is ranked lower than
64% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.89 vs. PKI: 73.43 )
Ranked among companies with meaningful Days Sales Outstanding only.
PKI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.62  Med: 75.88 Max: 82.98
Current: 73.43
61.62
82.98
Days Payable 55.65
PKI's Days Payable is ranked higher than
50% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. PKI: 55.65 )
Ranked among companies with meaningful Days Payable only.
PKI' s Days Payable Range Over the Past 10 Years
Min: 45.11  Med: 55.79 Max: 64.02
Current: 55.65
45.11
64.02

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.48
PKI's Dividend Yield % is ranked lower than
80% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.82 vs. PKI: 0.48 )
Ranked among companies with meaningful Dividend Yield % only.
PKI' s Dividend Yield % Range Over the Past 10 Years
Min: 0.48  Med: 1.02 Max: 2.43
Current: 0.48
0.48
2.43
Dividend Payout Ratio 0.14
PKI's Dividend Payout Ratio is ranked higher than
92% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. PKI: 0.14 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PKI' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.14  Med: 0.25 Max: 28
Current: 0.14
0.14
28
Forward Dividend Yield % 0.48
PKI's Forward Dividend Yield % is ranked lower than
88% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.16 vs. PKI: 0.48 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.48
PKI's 5-Year Yield-on-Cost % is ranked lower than
88% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. PKI: 0.48 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PKI' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.48  Med: 1.02 Max: 2.43
Current: 0.48
0.48
2.43
3-Year Average Share Buyback Ratio 0.90
PKI's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 133 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. PKI: 0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PKI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -10.7  Med: 0.5 Max: 3.3
Current: 0.9
-10.7
3.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.54
PKI's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
66% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.31 vs. PKI: 1.54 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PKI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.55  Med: 1.39 Max: 43.03
Current: 1.54
0.55
43.03
Price-to-Median-PS-Value 1.67
PKI's Price-to-Median-PS-Value is ranked lower than
83% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. PKI: 1.67 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PKI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.39  Med: 0.98 Max: 1.68
Current: 1.67
0.39
1.68
Price-to-Peter-Lynch-Fair-Value 2.10
PKI's Price-to-Peter-Lynch-Fair-Value is ranked higher than
59% of the 32 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.75 vs. PKI: 2.10 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
PKI' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.94  Med: 3.1 Max: 18.34
Current: 2.1
0.94
18.34
Earnings Yield (Greenblatt) % 4.05
PKI's Earnings Yield (Greenblatt) % is ranked higher than
68% of the 269 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.54 vs. PKI: 4.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PKI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.7  Med: 4.1 Max: 9.4
Current: 4.05
1.7
9.4
Forward Rate of Return (Yacktman) % 17.38
PKI's Forward Rate of Return (Yacktman) % is ranked higher than
76% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.41 vs. PKI: 17.38 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PKI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -0.8  Med: 12 Max: 43.7
Current: 17.38
-0.8
43.7

More Statistics

Revenue (TTM) (Mil) $2,116
EPS (TTM) $ 2.12
Beta1.05
Short Percentage of Float3.24%
52-Week Range $45.35 - 58.37
Shares Outstanding (Mil)109.79

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 2,282 2,338 2,422
EPS ($) 2.81 3.18 3.46
EPS without NRI ($) 2.81 3.18 3.46
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.46%
Dividends per Share ($) 0.28 0.29 0.30
» More Articles for PKI

Headlines

Articles On GuruFocus.com
Mawer New Canada Fund's Top New Buys Aug 21 2014 

More From Other Websites
PerkinElmer (PKI) Up 2% Since Earnings Report: Can It Continue? Mar 08 2017
PERKINELMER INC Financials Mar 04 2017
PERKINELMER INC Files SEC form 10-K, Annual Report Feb 28 2017
Perkinelmer to Present at Barclays Capital Global Healthcare Conference Feb 16 2017
PerkinElmer, Inc. (United States) :PKI-US: Earnings Analysis: 2016 By the Numbers : February 8, 2017 Feb 08 2017
PerkinElmer, Inc. (United States) :PKI-US: Earnings Analysis: Q4, 2016 By the Numbers : February 6,... Feb 06 2017
PerkinElmer (PKI) Misses Q4 Earnings & Revenue Estimates Feb 03 2017
PerkinElmer downgraded by BofA/Merrill Feb 03 2017
Edited Transcript of PKI earnings conference call or presentation 2-Feb-17 10:00pm GMT Feb 02 2017
PerkinElmer 4th qtr profit misses expectations Feb 02 2017
PERKINELMER INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 02 2017
PerkinElmer misses Street 4Q forecasts Feb 02 2017
PerkinElmer misses Street 4Q forecasts Feb 02 2017
PerkinElmer Announces Financial Results for Fourth Quarter and Full Year 2016 Feb 02 2017
Q4 2016 PerkinElmer Inc Earnings Release - After Market Close Feb 02 2017
PerkinElmer, Inc. (United States) breached its 50 day moving average in a Bullish Manner : PKI-US :... Feb 01 2017
PerkinElmer Board Declares Quarterly Dividend Jan 27 2017
PERKINELMER INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Jan 27 2017
Will PerkinElmer (PKI) Disappoint this Earnings Season? Jan 27 2017
PerkinElmer, Inc. (United States) breached its 50 day moving average in a Bearish Manner : PKI-US :... Jan 20 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)